Samlyn Capital LLC Acquires 28,312 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Samlyn Capital LLC raised its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 9.6% during the second quarter, HoldingsChannel reports. The fund owned 324,703 shares of the company’s stock after purchasing an additional 28,312 shares during the quarter. Samlyn Capital LLC’s holdings in Janux Therapeutics were worth $13,602,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Capstone Investment Advisors LLC bought a new stake in Janux Therapeutics during the 1st quarter valued at $1,969,000. Janus Henderson Group PLC raised its holdings in Janux Therapeutics by 1.8% during the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after acquiring an additional 34,069 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in Janux Therapeutics during the 1st quarter valued at $739,000. Virtu Financial LLC bought a new stake in Janux Therapeutics during the 1st quarter valued at $609,000. Finally, Vanguard Group Inc. raised its holdings in Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after acquiring an additional 378,477 shares during the period. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Performance

Shares of NASDAQ:JANX opened at $50.26 on Tuesday. Janux Therapeutics, Inc. has a 52-week low of $5.65 and a 52-week high of $65.60. The firm has a fifty day moving average of $43.69 and a 200 day moving average of $44.37. The firm has a market capitalization of $2.61 billion, a PE ratio of -41.20 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The company had revenue of $8.90 million during the quarter, compared to analyst estimates of $0.77 million. The firm’s revenue for the quarter was up 709.1% compared to the same quarter last year. On average, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.18 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00. Following the completion of the transaction, the insider now directly owns 3,162,851 shares in the company, valued at $132,839,742. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 268,578 shares of company stock worth $12,071,151. Corporate insiders own 35.40% of the company’s stock.

Analyst Upgrades and Downgrades

JANX has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a report on Monday, August 19th. Wedbush reaffirmed an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Stifel Nicolaus started coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a report on Monday, September 16th. Finally, Scotiabank decreased their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Janux Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $66.13.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.